Effects of novel vaccines on weight loss in diet-induced-obese (DIO) mice

Journal of Animal Science and Biotechnology

Volumn 3, Issue 1, 2012, Pages

  Haffer, Keith N ^a  

^a Braasch Biotech LLC   (United States)

Author keywords

Obesity Treatment; Vaccines; Weight loss; Weight management

Indexed keywords

EID: 84885365959     PISSN: 16749782     EISSN: 20491891     Source Type: Journal    
DOI: 10.1186/2049-1891-3-21     Document Type: Article

References (18)

1. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States- no change since 2003-2004 2007, National Center for Health Statistics, Hyattsville, MD, NCHS data brief no 1.
2. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005, 293:1861-1867. 10.1001/jama.293.15.1861, 15840860.
3. Daughaday WH, Hall K, Raben MS, Salmon WD, Brande JL, Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 1972, 235:107-109. 10.1038/235107a0, 4550398.
4. Johansen T, Malmlof K. Treatment of obesity using GH. Metab Syndr Relat Dis 2006, 4:57-69.
5. Franco C, Bengtsson BA, Johannsson G. The GH/IGF-1 axis in obesity: physiological and pathological aspects. Metab Syndr Relat Dis 2006, 4:51-56.
6. Vickers MH, Ikenasio BA, Breier BH. Adult growth hormone treatment reduces hypertension and obesity induced by an adverse prenatal environment. J Endocrinol 2002, 175:615-623. 10.1677/joe.0.1750615, 12475373.
7. Patel YC, Srikant CB. Somatostatin and its receptors. Adv Mol Cell Endocrinol 1999, 3:43-73.
8. Spencer GS. Hormonal systems regulating growth. A review. Livest Prod Sci 1985, 12:31-46.
9. Estrada A, Laarveld B, Bing L, Redmond M. Induction of systemic and mucosal immune responses following immunization with somatostatin-avidin complexes incorporated into Iscoms. Immunol Invest 1995, 24:819-828. 10.3109/08820139509060709, 8543345.
10. Fuller MF. The Encyclopedia of Farm Animal Nutrition 2004, 280-285. CABI Publishing.
11. Clee SM, Attie AD. The genetic landscape of type 2 diabetes in mice. Endocr Review 2006, 2:48-83.
12. The Jackson Laboratory Type 2 diabetes and obesity research and the laboratory mouse 2007, A Jackson Laboratory Resource Manual, The Jackson Laboratory.
13. Mendelsohn AR, Haffer KN, Larrick J. Chloramphenicol acetyl transferase (CAT)-defective somatostatin fusion protein and uses thereof 2010, United States Patent, US 7,722,881B2.
14. Haffer KN, Larrick J, Mendelsohn AR. Compositions and methods for enhanced somatostatin immunogenicity in the treatment of growth hormone and insulin-like growth factor one deficiency 2011, United States Patent Application Publication, US 2011/0195080A1.
15. Shirvill J. Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates 2010, Business Insights.
16. Lewendon A, Murray IA, Shaw WV, Gibbs MR, Leslie AG. Replacement of catalytic histidine-195 of chloramphenicol acetyl transferase. Evidence for a general role for glutamate. Biochemistry 1994, 33:1944-1950. 10.1021/bi00173a043, 7906544.
17. Guillemin R, Gerich JE. Somatostatin: Physiological and clinical significance. Ann Rev Med 1976, 27:379-388. 10.1146/annurev.me.27.020176.002115, 779605.
18. Lunin VG, Sergienko OV, Khodun ML, Bader LB, Karpov VA, Tikhomento TI. Chimeric somatostatin containing protein encoding DNA, plasmids of expression, methods for preparing chimeric protein, strain-producers, immunogenic composition, method for increasing the productivity of farm animals 2001, United States Patent, US 6,316,004B1.